Former United Therapeutics CEO joins Pluristem strategic advisory board

Company prepares for expansion, commercialization.

March 29, 2018 04:06
1 minute read.
Former United Therapeutics CEO joins Pluristem strategic advisory board

Roger Jeffs. (photo credit: Courtesy)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Pluristem Therapeutics Inc., the Haifa-based developer of placenta-based cell therapy products, announced earlier this week that Roger Jeffs has joined the company’s advisory board. Jeffs will advise Pluristem on clinical and commercial strategies.

Jeffs is the former president and CEO of the biotechnology company United Therapeutics, which has 12 locations throughout North America, the United Kingdom, China and Germany. In that role, he helped lead the company’s initial offering, oversaw the clinical development and regulatory approval of six products, and managed the commercial effort that lead to a significant increase in revenues.

“Dr. Jeffs brings tremendous expertise and vision to Pluristem – from business aspects to clinical development, marketing approval and commercialization,” said Pluristem chairman and co-CEO Zami Aberman.

“His work in developing Neupogen is directly relevant to our PLX-R18 clinical program in the treatment of bone marrow deficiencies.”

Neupogen is a daily white blood cell booster used to treat low blood neutrophils due to causes such as chemotherapy, radiation poisoning or HIV/AIDS.

Aberman explained that bringing Jeffs onto the advisory board is part of the company’s process of forming a senior strategic advisory board for support with expansion and commercialization.

Pluristem has reported clinical trial data in multiple indications for its patented PLX cells and is entering late-stage trials in several indications. Jeff’s said he believes in the potential effectiveness of the cell therapy solution.

“Pluristem’s placental cell therapies, currently being evaluated in multiple advanced clinical trials, could significantly advance regenerative medicine and make a change in the way patients are treated today, by delivering a safe and effective off-the-shelf cell therapy,” Jeffs said.

Before coming to United Therapeutics, Jeffs worked at Amgen Inc., where he helped lead the clinical program for Neupogen.

He currently serves on the boards of five public companies and is co-founder and co-owner of Bull City Select Investments.

“l look forward to working with Pluristem’s management team to move the clinical programs forward toward marketing,” Jeffs said.

This article was written in cooperation with Pluristem Therapeutics.

Related Content

An illustration of a radiologist analyzing a head CT scan
June 17, 2019
Zebra Medical wins FDA clearance for AI intracranial hemorrhage detection


Cookie Settings